Adam D. Cohen

18.3k total citations · 1 hit paper
201 papers, 6.0k citations indexed

About

Adam D. Cohen is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Adam D. Cohen has authored 201 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Hematology, 91 papers in Oncology and 90 papers in Molecular Biology. Recurrent topics in Adam D. Cohen's work include Multiple Myeloma Research and Treatments (98 papers), CAR-T cell therapy research (59 papers) and Protein Degradation and Inhibitors (32 papers). Adam D. Cohen is often cited by papers focused on Multiple Myeloma Research and Treatments (98 papers), CAR-T cell therapy research (59 papers) and Protein Degradation and Inhibitors (32 papers). Adam D. Cohen collaborates with scholars based in United States, United Kingdom and Canada. Adam D. Cohen's co-authors include Dan T. Vogl, Edward A. Stadtmauer, Alfred L. Garfall, Raymond L. Comenzo, Brendan M. Weiss, Jedd D. Wolchok, Kerry S. Campbell, Jean Boyer, David B. Weiner and Alan N. Houghton and has published in prestigious journals such as New England Journal of Medicine, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Adam D. Cohen

193 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

2015 434 citations Alfred L. Garfall, Simon F. Lacey et al. profile →

Peers

Countries citing papers authored by Adam D. Cohen

Since Specialization

Citations

This map shows the geographic impact of Adam D. Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam D. Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam D. Cohen more than expected).

Fields of papers citing papers by Adam D. Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam D. Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam D. Cohen. The network helps show where Adam D. Cohen may publish in the future.

Co-authorship network of co-authors of Adam D. Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Adam D. Cohen. A scholar is included among the top collaborators of Adam D. Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam D. Cohen. Adam D. Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes of radiation integrated with T-cell–engaging bispecific antibodies in relapsed/refractory multiple myeloma 2025 ·Blood Advances ·(unknown), Harper Hubbeling, Kang Yu, (unknown), Michael J. LaRiviere, John P. Plastaras, Adam D. Cohen, (unknown), Dan T. Vogl, Adam Waxman, Edward A. Stadtmauer, Alfred L. Garfall, Sandra P. Susanibar-Adaniya	0
2	BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement. 2024 ·Journal of Clinical Oncology ·Mahmoud Gaballa, Omar Castañeda Puglianini, Adam D. Cohen, Dan T. Vogl, Alfred Chung, Christopher J. Ferreri, Peter M. Voorhees, Doris K. Hansen, Krina K. Patel	1
3	Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma 2024 ·Bone Marrow Transplantation ·(unknown), (unknown), Jonathan Sussman, Alfred L. Garfall, Adam D. Cohen, (unknown), Sandra P. Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Edward A. Stadtmauer	2
4	MM-493 Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) With Lenalidomide (R) Maintenance Versus R Maintenance Alone in Adult Patients With Newly Diagnosed Multiple Myeloma (NDMM) Who Have Suboptimal Response to Autologous Stem Cell Transplantation (ASCT): Phase 3 KarMMa-9 Trial 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Noopur Raje, Adam D. Cohen, (unknown), Shaji Kumar, Aurore Perrot, Fredrik Schjesvold, Hermann Einsele, Paula Rodríguez‐Otero, (unknown), Carlos Fernández de Larrea, (unknown), Anna Truppel-Hartmann, (unknown), Fan Wu, Xiaobo Zhong, (unknown), Mihaela Popa, Mark Cook, María-Victoria Mateos	1
5	PCR134 Psychometric Properties of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Analysis of Phase 2 CARTITUDE-2 Study Cohorts A, B, and C 2024 ·Value in Health ·(unknown), Adam D. Cohen, (unknown), Mounzer Agha, Jesús F. San Miguel, (unknown), Niels W.C.J. van de Donk, (unknown), (unknown), (unknown), (unknown), (unknown), Helen Varsos, (unknown), William Deraedt, Mythili Koneru, (unknown), (unknown), (unknown)	0
6	Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma 2023 ·Oncology and Therapy ·Sundar Jagannath, (unknown), Concetta Crivera, (unknown), Carolyn C. Jackson, Satish Valluri, (unknown), (unknown), (unknown), (unknown), (unknown), Xueting Yu, Adam D. Cohen	17
7	Multiple airway plasmacytomas: A rare cause of proximal airway obstruction requiring tumor debulking 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Gabriel C. Caponetti, John P. Plastaras, Devraj Basu, Adam D. Cohen, C. Kevin	1
8	Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy 2023 ·Blood ·Yan Tang, Wei Liu, (unknown), Omar Johnson, Zainul S. Hasanali, (unknown), Alexander A. Shestov, Raymone Pajarillo, (unknown), Matthew Holmes, Liping Wang, Natalie Shih, Roddy S. O’Connor, Marco Ruella, Alfred L. Garfall, David Allman, Dan T. Vogl, Adam D. Cohen, Carl H. June, Neil C. Sheppard	9
9	POSTER: MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Yi Lin, Thomas Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, Abhinav Deol, Myo Htut, Alexander M. Lesokhin, Nikhil C. Munshi, Elizabeth O’Donnell, Carolyn C. Jackson, Tzu‐Min Yeh, Arnob Banerjee, Enrique Zudaire, Deepu Madduri, Christopher del Corral, Lida Pacaud, Sundar Jagannath	1
10	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma 2021 ·Clinical Cancer Research ·(unknown), Adam D. Cohen, Simon F. Lacey, Megan M. Davis, Alfred L. Garfall, J. Joseph Melenhorst, Russell Maxwell, W. Tristram Arscott, Amit Maity, Joshua Jones, John P. Plastaras, Edward A. Stadtmauer, Bruce L. Levine, Carl H. June, Michael C. Milone, Ima Paydar	23
11	Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Craig W. Freyer, Erin M. Bange, Sarah Skuli, (unknown), John K. Lin, Adam Cuker, Adam D. Cohen, Alfred L. Garfall	9
12	Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma 2019 ·Cancer Immunology Research ·Adam D. Cohen, Nikoletta Lendvai, Sarah Nataraj, Naoko Imai, Achim A. Jungbluth, (unknown), Adeeb Rahman, (unknown), (unknown), (unknown), Seunghee Kim‐Schulze, Andrew Park, Ralph Venhaus, Katherine Alpaugh, Sacha Gnjatic, (unknown)	14
13	How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma 2019 ·Clinical Cancer Research ·Adam D. Cohen, Noopur Raje, Jessica Fowler, Khalid Mezzi, Emma Scott, Madhav V. Dhodapkar	82
14	Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma 2019 ·Cancer Immunology Research ·Tatiana Pazina, Ashley M. James, (unknown), Yibin Yang, Andrew N. Gale, (unknown), (unknown), Robert F. Graziano, Natalie Bezman, Michael Robbins, Adam D. Cohen, Kerry S. Campbell	34
15	Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) 2019 ·Blood ·Caitlin Costello, Tara Gregory, Syed Abbas Ali, Jesús G. Berdeja, Krina K. Patel, Nina Shah, Eric Ostertag, Chris Martin, Majid Ghoddusi, Devon J. Shedlock, Matthew A. Spear, Robert Z. Orlowski, Adam D. Cohen	43
16	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis 2017 ·Blood ·Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, Jeffrey A. Zonder, Adam D. Cohen, David C. Seldin, Angela Dispenzieri, Arnaud Jaccard, Stefan Schönland, Deborah Berg, Huyuan Yang, Neeraj Gupta, Ai-Min Hui, Raymond L. Comenzo, Giampaolo Merlini	101
17	Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma 2016 ·Clinical Cancer Research ·Noopur Raje, Edward A. Faber, Paul G. Richardson, Gary J. Schiller, Raymond J. Hohl, Adam D. Cohen, Andres Forero, Susan P. Carpenter, Tuan S. Nguyen, Ilaria Conti, Christopher Kaiser, Damien M. Cronier, James E. Wooldridge, Kenneth C. Anderson	22
18	GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability 2013 ·Cancer Immunology Research ·David Schaer, Sadna Budhu, Cailian Liu, Campbell Bryson, (unknown), Adam D. Cohen, Hong Zhong, Xia Yang, Alan N. Houghton, Taha Merghoub, Jedd D. Wolchok	121
19	Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation 2010 ·PLoS ONE ·Adam D. Cohen, David Schaer, Cailian Liu, Yanyun Li, (unknown), (unknown), Adi Diab, Gabrielle Rizzuto, Fei Duan, Miguel‐Angel Perales, Taha Merghoub, Alan N. Houghton, Jedd D. Wolchok	199
20	Immune Rejection of Mouse Tumors Expressing Mutated Self 2009 ·Cancer Research ·Fei Duan, Yun Lin, Cailian Liu, Manuel E. Engelhorn, Adam D. Cohen, Michael A. Curran, Shimon Sakaguchi, Taha Merghoub, Stephanie Terzulli, Jedd D. Wolchok, Alan N. Houghton	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact